Details About Generic Salt ::  Amphoter

Main Medicine Class:: Anti-infective,antifungal   

(am-foe-TER-ih-sin B)

Amphotec

Class: Anti-infective/antifungal

 

Drugs Class ::

 Action Alters fungal cell membrane permeability.

Indications for Drugs ::

 Indications Treatment of invasive aspergillosis when renal impairment or unacceptable toxicity precludes use of amphotericin B deoxycholate and where prior amphotericin B deoxycholate therapy has failed.

Drug Dose ::

 Route/Dosage

ADULTS AND CHILDREN: Test dose: IV Infusion of small amount of final preparation (eg, 10 ml containing 1.6 to 8.3 mg) over 15 to 30 min and observe the patient carefully for 30 min. Initial dose: IV 3 to 4 mg/kg as required at a rate of 1 mg/kg/hr. Dose may be increased to 6 mg/kg if no improvement or there is evidence of progression of the fungal infection.

Contraindication ::

 Contraindications Hypersensitivity to amphotericin B, unless condition requiring treatment is life-threatening and amenable only to amphotericin B.

Drug Precautions ::

 Precautions

Pregnancy: Category B. Lactation: Undetermined. Nephrotoxicity: Drug is toxic; use with caution under close supervision; however, amphotericin B frequently is the only effective treatment for potentially fatal fungal diseases.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CV: Hypotension; tachycardia; hypertension; arrhythmia; edema. CNS: Headache; confusion; depression; abnormal thinking. DERM: Sweating; rash; pruritus. EENT: Eye hemorrhage. GI: Nausea, vomiting; abdominal pain. GU: Increased creatinine; hematuria; kidney failure. HEMA: Thrombocytopenia. HEPA: Abnormal liver function tests; bilirubinemia. META: Hypokalemia; hypomagnesemia; hypocalcemia; hyperglycemia. RESP: Dyspnea; hypoxia; epistaxis, increased cough; hemoptysis; hyperventilation; apnea. OTHER: Chills; fever; pain; anaphylactoid reactions.

Drug Mode of Action ::  

 Action Alters fungal cell membrane permeability.

Drug Interactions ::

 Interactions

Antineoplastic agents: Enhanced potential for nephrotoxicity, bronchospasm and hypotension. Corticosteroids: Increased potential for hypokalemia. Cyclosporine, tacrolimus: May increase nephrotoxic effects. Flucytosine: Increased flucytosine toxicity. Nephrotoxic agents (eg, aminoglycosides): Possible synergistic nephrotoxicity. INCOMPATIBILITIES: Do not mix with other medications.

Drug Assesment ::

 Assessment/Interventions

• Monitor patient closely during test administration for fever, chills, headache, nausea or vomiting.
• Obtain patient history, including drug history and any allergies.
• Ensure that fungal culture (blood or urine, as appropriate) of organism has been obtained before beginning therapy.
• Monitor pulse and BP every 15 min during test dose.
• Monitor IV injection site closely during administration for signs of infiltration.
• Monitor laboratory values, including liver function tests, CBC, renal function tests, potassium and magnesium levels.
• Monitor I&O during therapy.
• Monitor temperature 4 hr after administration; may be elevated.
• If patient experiences infusion-related symptoms (eg, chills, fever, hypotension, nausea), antihistamines and corticosteroids may be given before the infusion. Reducing the rate of infusion also may be helpful.

OVERDOSAGE: SIGNS & SYMPTOMS   Cardio-respiratory arrest

Drug Storage/Management ::

 Administration/Storage

• Reconstitute using only Sterile Water for Injection. Further dilution can be made with 5% Dextrose in water. Do not admix with saline or electrolytes or fluids containing preservatives.
• Do not mix with any other drug. Administer through separate IV line or flush existing line with 5% dextrose in water.
• Give test dose before full IV dose.
• Administer full dose at 1 mg/kg/hr.
• Administer IV form only to patients who are hospitalized or in an outpatient medical facility under close supervision.
• Do not administer solutions that have precipitates or foreign matter.
• Unopened vials can be stored at room temperature (59° to 86°F) until reconstituted.
• Wear gloves during reconstitution and administration.
• Reconstituted solutions can be stored under refrigeration (36° to 46°F) and used within 24 hr. Discard any unused solution.

Drug Notes ::

 Patient/Family Education

• Explain need for prolonged therapy and for close monitoring during course of therapy.
• Encourage patient to increase fluid intake to 2000 to 3000 ml/day if allowed.
• Inform patient to report any discomfort at injection site immediately.
• Instruct patient to report symptoms of chills, malaise, or fever.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.